Friday, June 24, 2011
Millennium, of Cambridge, Mass., a unit of the Takeda Oncology Co., presented data from an ongoing Phase II trial of Aurora A kinase inhibitor MLN8237 for B-cell and T-cell non-Hodgkin lymphoma. In 41 evaluable patients, MLN8237 treatment resulted in a 32 percent overall response rate and a 12 percent complete response rate. The data were presented at the International Congress on Malignant Lymphoma.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.